Glenmark receives ANDA approval for generic version of Vesicare® Tablets

May 21, 2019 | Tuesday | News

It is a generic version of Vesicare® Tablets, 5 mg and 10 mg, of Astellas Pharma US

Glenmark Pharmaceuticals has been granted final approval by the USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg, a generic version of Vesicare® Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc.

According to IQVIATM sales data for the 12 month period ending March 2019, the Vesicare® Tablets, 5 mg and 10 mg market achieved annual sales of approximately $942.7 million.

Glenmark’s current portfolio consists of 154 products authorized for distribution in the U.S. marketplace and 58 ANDA’s pending approval with the U.S. FDA.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy